<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although treatments have improved patient prognosis in surgically resectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, new effective drugs with improved safety profiles are needed to improve the currently poor outcomes of patients with recurrent or <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="8711">Quinacrine</z:chebi>, a small molecule anti-malarial agent that has activity in <z:e sem="disease" ids="C0017536" disease_type="Disease or Syndrome" abbrv="">giardiasis</z:e>, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>, <z:e sem="disease" ids="C0162534" disease_type="Disease or Syndrome" abbrv="">prion disease</z:e>, and used as a means of non-surgical sterilization, has shown cytotoxic activity across a broad range of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we evaluate the potential of adding <z:chebi fb="1" ids="8711">quinacrine</z:chebi> to anticancer chemotherapeutics and targeted agents as a potential novel combinatorial therapy for advanced <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We show that <z:chebi fb="1" ids="8711">quinacrine</z:chebi> synergizes with <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> and significantly enhances the cytotoxicity of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> in a panel of 10 human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines, including those with KRAS mutations protein gel blot analysis confirmed that <z:chebi fb="1" ids="8711">quinacrine</z:chebi>'s anticancer activity partially arises from its ability to stabilize p53 and lower anti-apoptotic protein levels </plain></SENT>
<SENT sid="4" pm="."><plain>In a series of in vivo studies, <z:chebi fb="1" ids="8711">quinacrine</z:chebi> monotherapy lowered the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load of nu/nu mice bearing human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> xenografts </plain></SENT>
<SENT sid="5" pm="."><plain>In combination, <z:chebi fb="1" ids="8711">quinacrine</z:chebi> and <z:chebi fb="0" ids="46345">5-Fluorouracil</z:chebi> significantly delayed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> of a variety of different xenografts, as compared to each agent administered alone </plain></SENT>
<SENT sid="6" pm="."><plain>Our results suggest that the administration of <z:chebi fb="1" ids="8711">quinacrine</z:chebi> in combination with chemotherapeutic agents and targeted agents should be further explored in patients with recurrent, locally advanced, or <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
</text></document>